| Trial ID: | L0720 |
| Source ID: | NCT01017276
|
| Associated Drug: |
Asp1585
|
| Title: |
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|Renal Dialysis|Renal Insufficiency
|
| Interventions: |
DRUG: ASP1585
|
| Outcome Measures: |
Primary: Serum phosphorus level at treatment discontinuation, During the 12-week treatment period | Secondary: Percent of the patients meeting the target range of serum phosphorus levels, During treatment|Time-course changes in serum calcium levels, During Treatment|Changes in serum Ca x P, During Treatment|Changes in intact PTH levels, During Treatment
|
| Sponsor/Collaborators: |
Sponsor: Astellas Pharma Inc
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
35
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2009-11
|
| Completion Date: |
2010-09
|
| Results First Posted: |
|
| Last Update Posted: |
2015-05-04
|
| Locations: |
Chubu, Japan|Chugoku, Japan|Kantou, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01017276
|
